Surgery in Treating Patients With Resectable Pancreatic Neoplasms
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
Immunologic Studies of Tumors of the Pancreas
RATIONALE: Surgery may be an effective way to treat pancreatic neoplasms.
PURPOSE: This clinical trial is studying how well surgery works in treating patients with
resectable pancreatic neoplasms.
OBJECTIVES:
Primary
- Obtain tumor tissue and lymphocytes, to identify tumor-specific antigens and their
HLA-restricted epitopes, from patients with resectable pancreatic neoplasms or
suspected mass undergoing standard surgical resection.
Secondary
- Determine survival of patients treated with this regimen.
OUTLINE: All patients are assessed to verify tumor resectability. Patients with disease
outside the pancreatic resection bed (portal vein or superior mesenteric vein involvement)
are removed from the study. All other patients undergo standard resection of the primary
tumor. Patients are then referred for appropriate adjuvant therapy or treatment under a
separate NIH protocol based on tumor histology.
After completion of study therapy, patients are followed at 1 month, every 3-4 months for 2
years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 180 patients (20 per histological type) will be accrued for
this study within 4-7 years.
We found this trial at
1
site
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
Click here to add this to my saved trials
